Navigation Links
Measurements fail to identify TB patients who could benefit from shorter treatment course
Date:6/30/2009

Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in resource-limited settings with poor public health infrastructures.

Testing whether two simple clinical measurements might help identify which TB patients could benefit from shorter treatment, researchers at Case Western Reserve University and University Hospitals (UH) Case Medical Center report that these measurements failed to work in a study published online by the American Journal of Respiratory and Critical Care Medicine.

The two measurements were absence of a cavity (an abscess caused by TB) in the lungs (detected by chest X-ray) and failure to grow TB bacteria from the sputum once drug treatment was started (sputum culture conversion). The Phase III clinical trial involved TB patients in Uganda (Africa), Brazil (S. America) and the Philippines (Asia) and was conducted by the Tuberculosis Research Unit (TBRU) at Case Western Reserve University and UH Case Medical Center in Cleveland, the only National Institutes of Health supported TB unit in the U.S.

"We found that combining these two clinical measurements failed to select TB patients who could benefit from shorter drug treatment. TB patients receiving four months of TB treatment had their disease come back much more often than those who got six months of drug treatment," said W. Henry Boom, M.D., an infectious disease expert with Case Western Reserve University and UH Case Medical Center and Director of the TBRU. "This study points out the limitations of current clinical measures to identify the relatively small group of TB patients who respond poorly to standard drug treatment."

"To better identify risk factors for why treatment fails in a subset of TB patients will require novel approaches and further research so that we can determine quickly (not having to wait for two years after completing six months of drug treatment to measure relapses) not only the effectiveness of new TB drugs or regimens but also who will benefit most from these shortened and simplified TB treatment regimens," added John L. Johnson, MD, first author of the study and an infectious disease expert with Case Western Reserve University School of Medicine and UH Case Medical Center.


'/>"/>

Contact: Alicia Reale
Alicia.Reale@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Measurements Poor for Assessing Clinical Trials With Children
2. Companies Utilize Variety of Metrics for Quality Measurements
3. Brain measurements could lead to better devices to move injured or artificial limbs
4. The Rasansky Law Firm Publishes Guide for Identifying, Preventing Childcare and Daycare Abuse
5. As college drinking problems rise, new studies identify effective prevention strategies
6. USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma
7. Researchers identify 4 new targets for breast cancer
8. Researchers identify four new targets for breast cancer
9. UNC scientists identify growth factor as possible cancer drug target
10. Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
11. Immunologists identify biochemical signals that help immune cells remember how to fight infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: